journal article·2012-12

Therapeutic nanoparticles from novel multiblock engineered polyesterurethanes

C. Mattu, M. Boffito, S. Sartori, E. Ranzato, E. Bernardi, M. P. Sassi, A. M. Di Rienzo, G. Ciardelli

Journal of Nanoparticle Research· Volume 14· Issue 12
Publisher page

Abstract

A novel biodegradable material belonging to the class of polyester-urethanes (PURs), based on poly(e-caprolactone) (PCL) blocks, was proposed as matrix-forming material for the preparation of nanoparticles by the solvent displacement method. This method has been widely applied to prepare nanoparticles with reproducible, small size with commercially available polyesters or polyester–polyether copolymers. These carriers often displayed fast and poorly controllable release rates. In response to these problems we proposed the insertion of polyesters into a more complex microstructure, such as that of polyurethanes, characterized by the alternation of hard and soft segments, in order to modulate and control the degradation rate and release profiles. PCL-based PUR (C-BC2000) was synthesized according to a two step synthesis procedure. Commercial PCL and poly(d, l lactide) (PLA) were used as controls; and paclitaxel, a potent anti-neoplastic drug, was encapsulated inside all carriers. Carriers prepared with the new material showed no intrinsic cytotoxicity (A-431 cells), with similar size in the range 211–226 nm and surface charge as the commercial controls. Moreover, C-BC2000 nanoparticles exhibited a slightly faster degradation rate, a much higher encapsulation efficiency (89 % against 24 % and 18 % for PLA and PCL, respectively) and a longer and more controlled release profile. This study highlighted the possibility to successfully employ biodegradable polyurethanes to prepare particles for controlled drug delivery, suggesting further and extensive investigation on the introduction of different PUR formulations in this field.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: biodegradable polymer synthesis and properties · Bone Tissue Engineering Materials · Flame retardant materials and properties

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (48)

Show source-provided references
1. Anhorn MG, Mahler H, Langer K (2008) Freeze drying of human serum albumin (HSA) nanoparticles with different excipients. Int J Pharm 363(1–2):162–169. doi: 10.1016/j.ijpharm.2008.07.00410.1016/j.ijpharm.2008.07.004 ↗
2. Bogdanov B, Toncheva V, Schacht E, Finelli L, Sarti B, Scandola M (1999) Physical properties of poly(ester-urethanes) prepared from different molar mass polycaprolactone-diols. Polymer 40:3171–3182. doi: 10.1016/S0032-3861(98)00552-710.1016/S0032-3861(98)00552-7 ↗
3. Bosworth LA, Downes S (2010) Physicochemical characterisation of degrading polycaprolactone scaffolds. Polym Degrad Stab 95(12):2269–2276. doi: 10.1016/j.polymdegradstab.2010.09.00710.1016/j.polymdegradstab.2010.09.007 ↗
4. Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Delivery Rev 54:631–651. doi: 10.1016/S0169-409X(02)00044-310.1016/S0169-409X(02)00044-3 ↗
5. Castro CA, Hogan JB, Benson KA, Shehata CW et al (1995) Behavioral effects of vehicles: DMSO ethanol, Tween-20, Tween-80 and emulphor-620. Pharmacol Biochem Behav 50(4):521–526. doi: 10.1016/0091-3057(94)00331-910.1016/0091-3057(94)00331-9 ↗
6. Cerrai P, Guerra CD, Lelli L, Tricoli M, Guerra RSD, Cascone MG, Giusti P (1994) Poly(ester-etherester) block copolymers as biomaterials. J Mater Sci Mater Med 5:33–3910.1007/BF00121151 ↗
7. Chawla JS, Amiji M (2002) Biodegradable poly(epsilon-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm 249:127–138. doi: 10.1016/S0378-5173(02)00483-010.1016/S0378-5173(02)00483-0 ↗
8. Chen DR, Bei JZ, Wang SG (2000) Polycaprolactone microparticles and their biodegradation. Polym Degrad Stab 67:455–459. doi: 10.1016/S0141-3910(99)00145-710.1016/S0141-3910(99)00145-7 ↗
9. Cheng Q, Feng J, Chen J, Zhu X, Li F (2008) Brain transport of neurotoxin-I with PLA nanoparticles through intranasal administration in rats: a microdialysis study. Biopharm Drug Dispos 29:431–439. doi: 10.1002/bdd.62110.1002/bdd.621 ↗
10. Ciardelli G, Rechichi A, Sartori S, D’Acunto M, Caporale A, Peggion E, Vozzi G, Giusti P (2006) Bioactive polyurethanes in clinical applications. Polym Adv Technol 17:786–789. doi: 10.1002/pat.78110.1002/pat.781 ↗
11. Deshpande D, Devalapally H, Amiji M (2008) Enhancement in anti-proliferative effects of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles. Pharm Res 25(8):1936–1947. doi: 10.1007/s11095-008-9614-310.1007/s11095-008-9614-3 ↗
12. Dhanikula AB, Panchagnula R (1999) Localized paclitaxel delivery. Int J Pharm 183:85–100. doi: 10.1016/S0378-5173(99)00087-310.1016/S0378-5173(99)00087-3 ↗
13. Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Delivery Rev 63:136–151. doi: 10.1016/j.addr.2010.04.00910.1016/j.addr.2010.04.009 ↗
14. Fessi H, Puisieux F, Devissaguet J, Ammoury N, Benita S (1989) Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55:R1–R4. doi: 10.1016/0378-5173(89)90281-010.1016/0378-5173(89)90281-0 ↗
15. Ge H, Hu Y, Yang S, Jiang X, Yang C (2000) Preparation, characterization, and drug release behaviors of drug-loaded ε-caprolactone/l-lactide copolymer nanoparticles. J Appl Polym Sci 75(7):874–882. doi: 10.1002/(SICI)1097-4628(20000214)75:7<874:AID-APP3>3.0.CO;2-G10.1002/(SICI)1097-4628(20000214)75:7<874::AID-APP3>3.0.CO;2-G ↗
16. Heijkants R, Van Calck RV, Van Tienen TG, De Groot JH, Buma P, Pennings AJ, Veth RPH, Schouten AJ (2005) Uncatalyzed synthesis, thermal and mechanical properties of polyurethanes based on poly(ε-caprolactone) and 1,4-butane diisocyanate with uniform hard segment. Biomaterials 26:4219–4228. doi: 10.1016/j.biomaterials.2004.11.00510.1016/j.biomaterials.2004.11.005 ↗
17. Kim D, Martin DC (2006) Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials 27:3031–3037. doi: 10.1016/j.biomaterials.2005.12.02110.1016/j.biomaterials.2005.12.021 ↗
18. Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B 75:1–18. doi: 10.1016/j.colsurfb.2009.09.00110.1016/j.colsurfb.2009.09.001 ↗
19. Kweon HE, Yoo MK, Park IK, Kim TH, Lee HC, Lee H, Oh J, Akaike T, Cho C (2003) A novel degradable polycaprolactone networks for tissue engineering. Biomaterials 24:801–808. doi: 10.1016/S0142-9612(02)00370-810.1016/S0142-9612(02)00370-8 ↗
20. Lambda NMK, Woodhouse KA, Copper SL, Lelah MD (1998) Polyurethanes in biomedical applications. CRC press, Bocs Raton
21. Leo E, Brina B, Forni F, Vandelli MA (2004) In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form. Int J Pharm 278:133–141. doi: 10.1016/j.ijpharm.2004.03.00210.1016/j.ijpharm.2004.03.002 ↗
22. Lince F, Marchisio DL, Barresi AA (2008) Strategies to control the particle size distribution of poly-ε-caprolactone nanoparticles for pharmaceutical applications. J Colloid Interface Sci 322:505–515. doi: 10.1016/j.jcis.2008.03.03310.1016/j.jcis.2008.03.033 ↗
23. Lince F, Bolognesi S, Stella B, Marchisio DL, Dosio F (2011) Preparation of polymer nanoparticles loaded with doxorubicin for controlled drug delivery. Chem Eng Res Des 89(11):2410–2419. doi: 10.1016/j.cherd.2011.03.01010.1016/j.cherd.2011.03.010 ↗
24. Martina M, Hutmacher DW (2007) Biodegradable polymers applied in tissue engineering research: a review. Polym Int 56:145–157. doi: 10.1002/pi.210810.1002/pi.2108 ↗
25. Martinotti S, Ranzato E, Burlando B (2011) In vitro screening of synergistic ascorbate–drug combinations for the treatment of malignant mesothelioma. Toxicol In Vitro 25(8):1568–157410.1016/j.tiv.2011.05.023 ↗
26. McDonald RT, McCarthy SP, Gross RA (1996) Enzymatic degradability of poly(lactide): effects of chain stereochemistry and material crystallinity. Macromolecules 29:7356–7361. doi: 10.1021/ma960513j10.1021/ma960513j ↗
27. McGuire WP, Markman M (2003) Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 89:S3–S810.1038/sj.bjc.6601494 ↗
28. Mora-Huertas CE, Fessi H, Elaissari A (2011) Influence of process and formulation parameters on the formation of submicron particles by solvent displacement and emulsification–diffusion methods critical comparison. Adv Colloid Interface Sci 163:90–12210.1016/j.cis.2011.02.005 ↗
29. Mu L, Feng SS (2003) A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release 86(1):33–48. doi: 10.1016/S0168-3659(02)00320-610.1016/S0168-3659(02)00320-6 ↗
30. Musumeci T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello R, Puglisi G (2006) PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm 325:172–179. doi: 10.1016/j.ijpharm.2006.06.02310.1016/j.ijpharm.2006.06.023 ↗
31. Panchagnula R (1998) Pharmaceutical aspects of paclitaxel. Int J Pharm 172(1–2):1–15. doi: 10.1016/S0378-5173(98)00188-410.1016/S0378-5173(98)00188-4 ↗
32. Penco M, Sartore L, Bignotti F, D’Antone S, Di Landro L (2000) Thermal properties of a new class of block copolymers based on segments of poly(d, l-lactic-glycolic acid) and poly(e-caprolactone). Eur Polymer J 36:901–908. doi: 10.1016/S0014-3057(99)00155-X10.1016/S0014-3057(99)00155-X ↗
33. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F (2006) Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2:8–21. doi: 10.1016/j.nano.2005.12.00310.1016/j.nano.2005.12.003 ↗
34. Rechichi A, Ciardelli G, D’Acunto M, Vozzi G, Giusti P (2008) Degradable block polyurethanes from nontoxic building blocks as scaffold materials to support cell growth and proliferation. J Biomed Mater Res A 84:847–855. doi: 10.1002/jbm.a.3134910.1002/jbm.a.31349 ↗
35. Ribeiro HS, Chu BS, Ichikawa S, Nakajima M (2008) Preparation of nanodispersions containing β-carotene by solvent displacement method. Food Hydrocoll 22:12–17. doi: 10.1016/j.foodhyd.2007.04.00910.1016/j.foodhyd.2007.04.009 ↗
36. Singh J, Pandit S, Bramwell VW, Alpar HO (2006) Diphtheria toxoid loaded poly(ε-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 38(2):96–105. doi: 10.1016/j.ymeth.2005.11.00310.1016/j.ymeth.2005.11.003 ↗
37. Stearns ME, Wang M (1992) Taxol blocks processes essential for prostate tumor cell (PC-3ML) invasion and metastases. Cancer Res 52:3776–3781
38. Tsuji H, Miyauchi S (2001) Poly(l-lactide): effects of crystallinity on enzymatic hydrolysis of poly(l-lactide) without free amorphous region. Polym Degrad Stab 71(3):415–424. doi: 10.1016/S0141-3910(00)00191-910.1016/S0141-3910(00)00191-9 ↗
39. Vermette P, Griesser HJ, Laroche G, Guidoin R (2001) Biomedical application of polyurethanes. Landes Bioscience, Georgetown
40. Vozzi G, Rechichi A, Dini F, Salvadori C, Vozzi F, Burchielli S, Carlucci F, Arispici M, Ciardelli G, Giusti P, Ahluwalia A (2008) PAM-microfabricated polyurethane scaffolds: in vivo and in vitro preliminary studies. Macromol Biosci 8:60–68. doi: 10.1002//mabi.200700211410.1002/mabi.200700214 ↗
41. Weiszhár Z, Czúcz J, Révész C, Rosivall J, Rozsnyay Z (2012) Complement activation by polyethoxylated pharmaceutical surfactants Cremophor-EL Tween-80 and Tween-20. Eur J Pharm Sci 45(4):492–498. doi: 10.1016/j.ejps.2011.09.01610.1016/j.ejps.2011.09.016 ↗
42. Wenk MR, Fahr A, Reszka R, Seelig J (1996) Paclitaxel partitioning into lipid bilayers. J Pharm Sci 85(2):228–231. doi: 10.1021/js950120i10.1021/js950120i ↗
43. Yen WC, Wientjes MG, Au JL (1996) Differential effect of taxol in rat primary and metastatic prostate tumors: site dependent pharmacodynamics. Pharm Res 13(9):1305–1312. doi: 10.1023/A:101605341258210.1023/A:1016053412582 ↗
44. Zanetti-Ramos BG, Lemos-Senna E, Soldi V, Borsali R, Cloutet E, Cramail H (2006) Polyurethane nanoparticles from a natural polyol via miniemulsion technique. Polymer 47:8080–8087. doi: 10.1016/j.polymer.2006.09.05710.1016/j.polymer.2006.09.057 ↗
45. Zanetti-Ramos BG, Lemos-Senna E, Cramail H, Cloutet E, Borsali R, Soldi V (2008) The role of surfactant in the miniemulsion polymerization of biodegradable polyurethane nanoparticles. Mater Sci Eng C 28(2008):526–531. doi: 10.1016/j.msec.2007.04.04110.1016/j.msec.2007.04.041 ↗
46. Zavisova V, Koneracka M, Strbak O, Tomasovicova N, Kopcansky P, Timko M, Vavra I (2007) Encapsulation of indomethacin in magnetic biodegradable polymer nanoparticles. J Magn Magn Mater 311:379–382. doi: 10.1016/j.jmmm.2006.11.17710.1016/j.jmmm.2006.11.177 ↗
47. Zhang Z, Feng SS (2006) Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 27:262–270. doi: 10.1016/j.biomaterials.2005.05.10410.1016/j.biomaterials.2005.05.104 ↗
48. Zili Z, Sfar S, Fessi H (2005) Preparation and characterization of poly-epsilon-caprolactone nanoparticles containing griseofulvin. Int J Pharm 294:261–267. doi: 10.1016/j.ijpharm.2005.01.02010.1016/j.ijpharm.2005.01.020 ↗